CRISPR Therapeutics AG (NASDAQ:CRSP) Holdings Raised by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 40.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 244,034 shares of the company’s stock after purchasing an additional 69,937 shares during the quarter. Vestmark Advisory Solutions Inc. owned about 0.29% of CRISPR Therapeutics worth $9,605,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CRSP. ARK Investment Management LLC lifted its stake in shares of CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after acquiring an additional 1,474,439 shares during the period. State Street Corp lifted its position in CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares during the period. FMR LLC boosted its stake in CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after purchasing an additional 23,075 shares in the last quarter. Geode Capital Management LLC increased its position in shares of CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares during the period. Finally, Baker BROS. Advisors LP raised its stake in shares of CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after buying an additional 743,075 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Up 0.9 %

Shares of NASDAQ:CRSP opened at $43.84 on Thursday. The firm has a market cap of $3.76 billion, a price-to-earnings ratio of -10.03 and a beta of 1.67. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $83.50. The business has a fifty day simple moving average of $42.57 and a 200 day simple moving average of $45.86.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John Greene bought 7,000 shares of the firm’s stock in a transaction on Wednesday, February 26th. The shares were bought at an average cost of $44.85 per share, with a total value of $313,950.00. Following the transaction, the director now directly owns 7,000 shares of the company’s stock, valued at approximately $313,950. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CRSP shares. Morgan Stanley lifted their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a report on Friday, February 14th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, February 13th. Stifel Nicolaus cut their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Finally, JMP Securities reiterated a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $74.40.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.